Carbonion-boost (C12) followed by radiochemotherapy with photons as organ preservingProcedure for SCC of the Nasal Vestibule

Introduction We report our experience of organ preserving, primary radiotherapy with carbon ion boost in SCCs of the anterior nasal cavity / nasal vestibule.

Methods 12 patients underwent organ preserving RT with C12-boost (24GyRBE) at Marburg Particle Therapy Center (MIT). Boost therapy was followed by radiochemotherapy (50-56Gy +/-SIB to 62,5Gy photons, in 75 % irradiation of lymphatic drain was performed, 66 % received cisplatin simultaneously). Age 62 years (mean). 50 % had T3/4 tumors; 41,6 % had T2 tumors. 1 patient presented with recurrent disease. 25 % were nodal positive. Mean boost volume 44ml. Mean FU 8 month.

Results During FU-period local control and loco regional control were 83, 3 % and 91, 6 % respectively. 1 patient underwent salvage surgery due to residual tumor after 7 month, 1 patient underwent salvage RT due to nodal recurrence after 18 month. Ultimate local and loco regional control, distant metastasis free survival and overall survival were 100 %. No acute toxicity >CTCAE°III was detected. 5 patients developed toxicity CTCAE °III (erythema, mucositis, dysphagia). 6 weeks after RT 1 CTCAE°III toxicity was detected (xerostomia). 3 month after RT 2 patients developed CTCAE°III toxicity (dysphagia).

Conclusion Primary chemoradiotherapy with C12 boost as an organ preserving procedure achieves high local control rates with good cosmetic results and is well tolerated.

Poster-PDF A-1873.PDF

Publication History

Article published online:
10 June 2020